Head and Neck Cancer Treatment Update: Pembrolizumab, Nivolumab and PD-L1 Markers

Head and Neck Cancer Treatment Update: Pembrolizumab, Nivolumab and PD-L1 Markers

cancergrace

2 years
1,379 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Drs. Jared Weiss, Assistant Professor, Clinical Research Hematology/Oncology, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, join GRACE to discuss updates relating to pembrolizumab, nivolumab and PD-L1 markers for head and neck cancers.
Up Next Autoplay